Lynn Macdonald is a Vice President at Regeneron heading the VelocImmune-NEXT Technology Development Group, Neuroscience Group, & Molecular Profiling Group. Lynn earned her B.S. in Molecular Genetics from the University of Rochester and her Ph.D. in Molecular Biology from Downstate Medical Center. She completed a post-doctoral fellowship at Columbia University before joining Cadus Pharmaceuticals in 1996. In 1999 she moved to Regeneron Pharmaceuticals, where she has been a key contributor to developing its ground-breaking VelociSuite of genomics technologies. Specifically, Lynn played a critical role in developing VelociGene®, a novel technology for the modification of the mouse genome, and subsequently worked as part of the team that developed the VelocImmune® Mouse. This humanized mouse strain has been used to develop fully human antibodies that can be rapidly translated into treatments for human disease. So far these technologies have led to three approved drugs and 15 antibodies, across multiple therapeutic areas, currently in clinic.